| 1 |
metastatic renal cell carcinoma
(1854 times)
|
Neoplasms
(1085 times)
|
OS (609 times)
PFS (516 times)
CI (203 times)
|
1992 Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies.
|
| 2 |
metastatic RCC
(144 times)
|
Neoplasms
(72 times)
|
RCC (128 times)
OS (26 times)
PFS (20 times)
|
2002 Therapeutic options in the management of renal cell carcinoma.
|
| 3 |
metastatic clear cell renal cell carcinoma
(18 times)
|
Neoplasms
(10 times)
|
TKI (4 times)
VEGF (4 times)
PFS (3 times)
|
2009 The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations.
|
| 4 |
metastatic clear cell renal cancer
(6 times)
|
Neoplasms
(4 times)
|
VEGF (3 times)
HR (2 times)
OS (2 times)
|
2011 Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
|
| 5 |
metastatic renal cell carcinoma patients
(2 times)
|
Pharmacokinetics
(1 time)
|
NLR (2 times)
OS (2 times)
DBP (1 time)
|
2017 A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.
|
| 6 |
murine renal cell carcinoma
(2 times)
|
Neoplasms
(2 times)
|
G250-FMLs (1 time)
MLs (1 time)
RCC (1 time)
|
2001 Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes.
|
| 7 |
metastatic kidney cancer
(1 time)
|
Health Services
(1 time)
|
AEs (1 time)
DI (1 time)
mDI (1 time)
|
2022 Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
|
| 8 |
metastatic primary ccRCCs
(1 time)
|
Neoplasms
(1 time)
|
ccRCC (1 time)
nmRCC (1 time)
|
2016 Opposite prognostic roles of HIF1alpha and HIF2alpha expressions in bone metastatic clear cell renal cell cancer.
|
| 9 |
metastatic renal cell carcinoma with clear cell component
(1 time)
|
Neoplasms
(1 time)
|
Ave-Axi (1 time)
Ipi-Nivo (1 time)
OS (1 time)
|
2020 Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
|
| 10 |
multilocular RCC
(1 time)
|
Neoplasms
(1 time)
|
ccRCC (1 time)
chRCC (1 time)
FoxM1 (1 time)
|
2015 Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
|
A Search Service for Abbreviation / Long Form